|
Clinical data for glaucoma and OHT patients |
|||||||||||
| Pat no. |
Age (yr) |
LE Condition |
LE VA |
LE VF loss |
LE CTmax |
RE Condition |
RE VA |
RE VF loss |
RE CTmax |
I-O diff |
R2 |
|
|
|||||||||||
| 1 |
72 |
POAG |
6/5 |
74% |
0.051 |
POAG |
6/4 |
7% |
0.023 |
0.025 |
79%* |
| 2 |
73 |
POAG |
6/6 |
60% |
0.098 |
POAG |
6/7.5 |
51% |
0.168 |
0.045 |
0%° |
| 3 |
67 |
POAG |
6/6 |
4% |
0.099 |
NPG |
6/9 |
53% |
0.107 |
0.004 |
48%+ |
| 4 |
76 |
POAG |
6/6 |
7% |
0.075 |
POAG |
6/7.5 |
44% |
0.078 |
0.001 |
1%° |
| 5 |
71 |
POAG |
6/6 |
36% |
0.142 |
POAG |
6/6 |
30% |
0.067 |
0.045 |
0%° |
| 6 |
66 |
POAG |
6/6 |
17% |
0.075 |
POAG |
6/12 |
7% |
0.091 |
0.014 |
-25%° |
| 7 |
77 |
POAG |
6/24 |
55% |
0.055 |
POAG |
6/6 |
67% |
0.044 |
0.012 |
14%° |
| 8 |
68 |
POAG |
6/6 |
23% |
0.069 |
normal |
6/5 |
4% |
0.049 |
0.019 |
55%* |
| 9 |
75 |
POAG |
6/9 |
44% |
0.102 |
normal |
6/5 |
1% |
0.041 |
0.034 |
85%* |
| 10 |
72 |
normal |
6/6 |
2% |
0.023 |
POAG |
6/9 |
42% |
0.031 |
0.006 |
47%+ |
| 11 |
37 |
POAG |
6/18 |
14% |
0.089 |
blind |
nil |
100% |
n/s |
na |
na |
| 12 |
83 |
POAG pxf |
6/9 |
1% |
0.066 |
POAG pxf |
6/9 |
51% |
n/s |
na |
na |
| 13 |
83 |
POAG pxf |
6/18 |
69% |
0.058 |
POAG pxf |
6/12 |
46% |
0.074 |
0.025 |
-24%° |
| 14 |
74 |
POAG pxf |
6/5 |
26% |
0.067 |
OHT |
6/6 |
3% |
0.056 |
0.008 |
9%° |
|
|
|||||||||||
| 15 |
73 |
NPG |
6/5 |
17% |
0.055 |
NPG |
6/5 |
47% |
0.033 |
0.014 |
0%° |
| 16 |
76 |
NPG |
6/9 |
18% |
0.150 |
NPG |
6/12 |
47% |
0.060 |
0.021 |
46%+ |
| 17 |
73 |
NPG |
6/9 |
53% |
0.048 |
normal |
6/9 |
4% |
0.027 |
0.010 |
49%+ |
| 18 |
54 |
RD |
6/12 |
2% |
0.046 |
NPG |
6/5 |
41% |
0.083 |
0.023 |
85%* |
|
|
|||||||||||
| 19 |
61 |
PCACG |
6/9 |
11% |
0.078 |
ACG |
6/9 |
3% |
0.072 |
0.012 |
na |
| 20 |
79 |
PTG |
6/9 |
55% |
0.147 |
normal |
6/9 |
6% |
0.077 |
0.055 |
26%° |
| 21 |
55 |
normal |
6/6 |
7% |
0.044 |
SIG |
6/6 |
52% |
0.058 |
0.017 |
73%* |
|
|
|||||||||||
| 22 |
70 |
OHT |
6/5 |
0%(2%) |
0.031 |
OHT |
6/5 |
0% (6%) |
0.018 |
0.002 |
na |
| 23 |
78 |
OHT |
6/5 |
0% (7%) |
0.022 |
OHT |
6/9 |
3% (8%) |
0.033 |
0.0064 |
na |
| 24 |
57 |
OHT |
6/5 |
6% (13%) |
0.054 |
OHT |
6/5 |
4%(13%) |
0.051 |
0.0006 |
na |
| 25 |
62 |
OHT |
6/5 |
2% (2%) |
0.034 |
OHT pdc |
6/12 |
4% (6%) |
0.042 |
0.010 |
na |
| 26 |
72 |
A OHT pdc |
6/60 |
8% (29%) |
0.155 |
OHT pdc |
6/12 |
8% (35%) |
0.059 |
0.068 |
na |
|
Pat no. Patient number, LE left eye, RE right eye, A amblyopic, CTmax highest contrast threshold value (to be compared against the upper prediction limit of 0.045), I-O diff inter-ocular difference (to be compared against the upper prediction limit of 0.006), NPG normal pressure glaucoma, OHT ocular hypertensive, na not applicable, n/s not seen, PCACG primary chronic angle closure glaucoma, pdc pathological cupping of optic disc, POAG primary open angle glaucoma, PTG post-traumatic glaucoma, pxf pseudoexfoliation, RD retinal detachment, SIG sarcoid-induced glaucoma, VA visual acuity, VF visual field. Negative R2 values denote inverse relationship. *p < 0.05, +0.05 <p < 0.10, °p > 0.10. Some eyes denoted normal show visual field loss due to the blind spot while some glaucomatous eyes showing minimal visual loss had additional loss either more peripheral or more central to the truncated quadrant. OHT patients also show visual field loss score in parenthesis at 12 months follow-up examinations. | |||||||||||
Tochel et al. BMC Ophthalmology 2005 5:22 doi:10.1186/1471-2415-5-22 |
|||||||||||